Skip to main content
. Author manuscript; available in PMC: 2014 Jul 9.
Published in final edited form as: Biochem Pharmacol. 2012 Jun 21;84(5):701–711. doi: 10.1016/j.bcp.2012.06.010

Table 2.

Primers used for preparation of mutated constructs of CYP3A4-P92-luc reporter gene The underlined letters indicated the restriction sites and highlight letters indicated mutant sites.

Primer Sequence(5’-3’)
CYP3A4(−92/−88Xhols) ATACTACTCGAGCGTCCCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−87/−83Xhols) ATACTACTCGAGGCAGGGTCTCCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−82/−78Xhols) ATACTACTCGAGGCAGGCAGAGGTGTCGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−77/−73Xhols) ATACTACTCGAGGCAGGCAGAGCACAGCACCGCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−72/−68Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCGGACGTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−67/−63Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCATGACGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−62/−58Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGCGACGAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(+4HindIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCTAGAGAAGGAGGCAGGGCTGGAGCT
CYP3A4(−57/−53Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCTCGAGCAGCCCTGCCTCCTTCTCTA
CYP3A4(−57/−53HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCTAGAGAAGGAGGCAGGGCTGCTCGA
CYP3A4(−52/−48Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCGTCGGCTGCCTCCTTCTCTA
CYP3A4(−52/−48HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCTAGAGAAGGAGGCAGCCGACGAGCT
CYP3A4(−47/−43Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCGACGGTCCTTCTCTA
CYP3A4(−47/−43HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCTAGAGAAGGACCGTCGGCTGGAGCT
CYP3A4(−42/−38Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCAGGAACTCTA
CYP3A4(−42/−38HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCTAGAGTTCCTGGCAGGGCTGGAGCT
CYP3A4(−37/−33Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTGAGAT
CYP3A4(−37/−33HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTATATGCATCTCAAGGAGGCAGGGCTGGAGCT
CYP3A4(−92Xhols) ATACTACTCGAGGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTA
CYP3A4(−32/−28HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTGTTTAATACGATCTCAAGGAGGCAGGGCTGGAGCT
CYP3A4(−27/−23HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTGGATTCAAATTATGCATCTCAAGGAGGCAGGGCTGGAGCT
CYP3A4(−22/−18HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGCTGTTCCTAAGTTTATATGCATCTCAAGGAGGCAGGGCTGGAGCT
CYP3A4(−17/−13HidIIIa) ATACTAAAGCTTCAGTGATTCAGTGAGGGACAAGGATTGTTTATATGCATCTCAAGGAGGCAGGGCTGGAGCT